Array Biopharma Spun Off Heart Drug R&D Into New Subsidiary Yarra Therapeutics
It appears that what Array is trying to do is focus on oncology while the new subsidiary focuses on rare diseases. Source: BioSpace
The Number 1 Small-Cap Biotech Investors are Missing Out On
A look at a small-cap biotech company that investors should consider. Source: BioSpace
Mallinckrodt Takes Out Sucampo in Surprising $1.2B Deal
Mallinckrodt picks up Sucampo’s Amitiza as well as two other pipeline compounds. Source: BioSpace
Maryland's Precision Medicine Group Lands $275M
The round was led by Berkshire Partners and TPG Growth, with participation from its co-founders and management team, as well as original investors Oak Investment Partners and J.H. Whitney. Source:…
SoCal's Peregrine Names a New CEO, to Change Name to Avid Bioservices
Dr. Lias succeeds Steven W. King, who resigned as president and chief executive officer of Peregrine to pursue other professional interests. Source: BioSpace
Shire Plans to Hire in 2018 for its Georgia Manufacturing Site
Shire filed its first submission to the FDA for its new plasma manufacturing site in Covington, Georgia. Source: BioSpace
Novartis' Tasigna Wins FDA Nod for First and Only CML Therapy With Treatment-Free Remission Data …
Novartis announced today that the FDA approved the inclusion of Treatment-free Remission data in the Tasigna U.S. product label. Source: BioSpace
Novartis Can be Sued for Damage Caused by Generics California Court Rules
In a result that could have far-reaching implications for brand-name drug manufacturers, the California Supreme Court unanimously ruled Novartis can be held liable for injuries caused by generics of its…
United Therapeutics Settles Federal Kickback Lawsuit for $210 Million
United Therapeutics agreed to pay $210 million to resolve Justice Department claims that the drugmaker collaborated with charity Caring Voice Coalition (CVC) to boost sales of United’s pulmonary arterial hypertension…
FDA Reminds Sponsors to Submit One-Time Orange Book Status Report
The FDA is requesting all NDA and ANDA holders to submit a one-time, written status report to the agency after reviewing the information published in the Orange Book. Source: Drug…